Ken Griffin Crinetics Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	SELL	$50.66 - $60.69 $587,656 - $704,004	-11,600 Reduced 60.42%	7,600 $388,000
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $688,131 - $863,186	15,700 Added 448.57%	19,200 $980,000
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $1.18 Million - $1.46 Million	-28,100 Reduced 88.92%	3,500 $156,000
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $740,388 - $997,053	21,300 Added 206.8%	31,600 $1.48 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $1.85 Million - $2.68 Million	-72,300 Reduced 87.53%	10,300 $366,000
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $1.25 Million - $2.4 Million	78,300 Added 1820.93%	82,600 $2.46 Million
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $66,066 - $99,120	4,200 Added 4200.0%	4,300 $77,000
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $15,310 - $21,100	-1,000 Reduced 90.91%	100 $1,000
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $17,039 - $20,955	1,100 New	1,100 $20,000

252

89.2M

26.1K

11.8K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.91B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.